ClinicalTrials.gg
CompletedNCT03082534Updated Oct 1, 2026Results posted

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

A Phase 2 interventional study of Pembrolizumab, Cetuximab in HNSCC, Lip SCC and Oral Cavity Cancer, sponsored by University of California, San Diego. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by University of California, San Diego · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Updated Oct 1, 2026Results postedStudy documents postedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck — 18 open to participants now, 32 under way, 2 of them phase 3. pembrolizumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
27th of 63
78 · median 50
Started
2017
with 6 others
Phase 2
44 of 63
14 open now
Registered
17th of 63
by date
Lead sponsor
2 of 63
University of California, San Diego

Among the 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck, this one is the 27th largest by enrollment, is one of 7 that started in 2017, is one of 44 in phase 2, and was the 17th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

18 of the 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck are open now, in 5 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing pembrolizumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This is a prospective, multi-center, open-label, non-randomized, multi-arm phase II trial to evaluate the efficacy of combination therapy with pembrolizumab and cetuximab for patients with recurrent/metastatic HNSCC. There will be four patient cohorts, including a PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve arm (Cohort 1), a PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve arm (Cohort 2), a PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory arm (Cohort 3), and a cutaneous HNSCC arm (Cohort 4). A total of 83 patients (33 in Cohort 1, 25 in Cohort 2, 15 in Cohort 3, and 10 in Cohort 4) will be eligible to enroll. Patients will be enrolled at 4 sites: UC San Diego Moores Cancer Center, UC Los Angeles Jonsson Comprehensive Cancer Center, University of Michigan Comprehensive Cancer Center, and University of Washington Siteman Cancer Center.

Read the detailed description

Primary Objectives:

To determine the clinical efficacy of pembrolizumab combined with cetuximab for patients with R/M HNSCC.

  1. Cohort 1 (PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve): clinical efficacy defined as overall response rate.
  2. Cohort 2 (PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve): clinical efficacy defined as overall response rate.
  3. Cohort 3 (PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory): clinical efficacy defined as overall response rate.
  4. Cohort 4 (cutaneous HNSCC): clinical efficacy defined as overall response rate.

Secondary Objectives:

  1. To determine 12 month progression-free survival probability.
  2. To determine overall survival.
  3. To determine duration of response.
  4. To assess safety and tolerability of pembrolizumab combined with cetuximab.
  5. To evaluate the correlation between molecular markers and disease outcome.
03

Conditions studied

  • HNSCC
  • Lip SCC
  • Oral Cavity Cancer
  • Oropharynx Cancer
  • Larynx Cancer
  • Hypopharynx Cancer
  • Nasopharynx Cancer
  • Sinonasal Carcinoma
  • Cutaneous Squamous Cell Carcinoma
  • Head and Neck Neoplasms
  • Head and Neck Cancer
  • Head and Neck Squamous Cell Carcinoma

Keywords

  • Head and Neck Cancer
  • Pembrolizumab
  • Keytruda®
  • Cetuximab
  • Erbitux®
  • Recurrent
  • Metastatic
  • PD-1
  • PD-L1
  • non-EBV related Nasopharynx
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all of the inclusion criteria to participate in this study.

  1. Ability to understand and the willingness to sign a written .
  2. or cytologically proven squamous cell carcinoma of the head and neck (lip, oral cavity, oropharynx, larynx, hypopharynx, non-EBV related nasopharynx, sinonasal, cutaneous), not amenable to curative intent therapy.
  3. Platinum- disease, or ineligible/unfit for platinum-based therapy
  4. Patients must have at least one measurable site of disease as defined by v.1.1, determined by investigator review
  5. Age ≥ 18 years.
  6. (ECOG) Performance status 0 or 1.
  7. Patient has adequate hematologic, hepatic and renal function
  8. Female patient of has a negative serum or urine pregnancy within 72 hours prior to receiving the first dose of study medication.
  9. Female patient of childbearing potential agrees to use 2 methods of or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication.
  10. Male patient with a partner of childbearing potential agrees to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.

Additional Inclusion Criterion for Cohort 1 (/PD-L1 Inhibitor-naïve, Cetuximab-naïve) and Cohort 2 (PD-1/PD-L1 Inhibitor-refractory, Cetuximab-naïve):

1. Cetuximab-naïve patients may not have received cetuximab therapy in the recurrent/ setting (treatment in curative setting permitted)

Additional Inclusion Criterion for Cohorts 2 and 3 (PD-1/PD-L1 Inhibitor-refractory):

1. PD-1/PD-L1 inhibitor-refractory patients must have documented disease progression after prior response to anti-PD-1/PD-L1 therapy (response defined as stable disease, partial or complete response)

Additional Inclusion Criterion for Cohort 4 (Cutaneous HNSCC):

1. Cutaneous HNSCC must not be amenable to local treatment modalities, including surgery and/or radiation.

Exclusion criteria

Exclusion Criteria:

Patients meeting any of the exclusion criteria at baseline will be excluded from study participation.

  1. Patient has salivary gland primary.
  2. Patient is currently receiving or has received another agent within 4 weeks prior to Day 1 of study.
  3. Patient has received chemotherapy or radiotherapy within 4 weeks prior to Day 1 of study. Prior palliative radiotherapy to lesion(s) is permitted, provided there is at least one that has not been radiated.
  4. Patient has received a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or baseline) from adverse events due to a previously administered agents.
  5. Patient has had major surgery or insufficient recovery from surgical-related trauma or wound healing within 14 days of Study Day 1.
  6. Patient has had a prior Grade ≥ 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > Grade 1.
  7. Patient has had prior Grade 4 infusion reaction to cetuximab.
  8. Patient has a known additional that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  9. Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

    Note: Patients with previously treated may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.

  10. Patient has an active disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or drugs).

    Notes:

    • Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment within the past 2 years are not excluded.
    • Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  11. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (>10mg prednisone daily, or steroid equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of pembrolizumab.
  12. Patient has a known history of active TB (Baccillus Tuberculosis).
  13. Patient has a known history of, or any evidence of active, non-infectious pneumonitis.
  14. Patient has a known history of chronic interstitial lung disease.
  15. Patient has an active infection requiring systemic therapy.
  16. Patient has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  17. Patient has a known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  18. Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial.
  19. Patient has known active infection (defined as presence of HepB sAg and/ or Hep B DNA), active infection (defined as presence of Hep C RNA) and/or known (HIV) carrier (HIV 1/2 antibodies).
  20. Patient has received a within 30 days of study Day 1.

Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

Additional Exclusion Criterion for Cohorts 1 (/PD-L1 inhibitor-naïve, cetuximab-naïve) and 4 (cutaneous):

1. Patient has received any prior immunotherapy with inhibitors of PD-1 or PD-L1.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Cohort 1

    PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve Pembrolizumab (Keytruda®): Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks. Cetuximab (Erbitux®): The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min).

    Drug: Pembrolizumab, Cetuximab

  • Experimental
    Cohort 2

    PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve Pembrolizumab (Keytruda®): Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks. Cetuximab (Erbitux®): The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min).

    Drug: Pembrolizumab, Cetuximab

  • Experimental
    Cohort 3

    PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory Pembrolizumab (Keytruda®): Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks. Cetuximab (Erbitux®): The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min).

    Drug: Pembrolizumab, Cetuximab

  • Experimental
    Cohort 4

    cutaneous HNSCC Pembrolizumab (Keytruda®): Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks. Cetuximab (Erbitux®): The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min).

    Drug: Pembrolizumab, Cetuximab

Interventions

  • DrugPembrolizumab, Cetuximab

    Drug pages: PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection. Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR.

    Also known as: Keytruda®, Erbitux®

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Proportion of patients with partial or complete response in tumor burden as defined by RECIST

    Time frame: 6 months from the time of study enrollment

Secondary outcomes

  1. Progression Free Survival

    No disease progression or death from any cause at 12 months from the time of study enrollment

    Time frame: 12 months from the time of study enrollment

  2. Overall Survival

    Time from study enrollment to death from any cause

    Time frame: From the time of study enrollment until the date of death from any cause or completion of study, whichever came first, assessed up to 36 months

  3. Duration of Response

    Time from documentation of tumor response to disease progression

    Time frame: Every 9 weeks from first on-treatment scan until disease progression or patient withdrawal from study or date of death from any cause, whichever came first, assessed up to 36 months

  4. Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Pembrolizumab and Cetuximab, Graded According to NCI CTCAE v4.03

    Description, grade (per CTCAE v4.03), seriousness and relatedness

    Time frame: Upon study enrollment, then subsequently at the first visit of each cycle (cycle length is 21 days), at the time of any adverse event, through end of treatment study visit, assessed up to 36 months

  5. Correlative Analyses

    Tumor tissue biomarkers correlated with outcome to pembrolizumab or cetuximab, such as PD-L1 expression, EGFR expression, p16 status, and immunophenotyping

    Time frame: Tumor specimens (archival or new specimen) should be obtained within 42 days of screening

  6. Correlative Analyses

    Blood biomarkers correlated with outcome to pembrolizumab or cetuximab, including T cell receptor (TCR) sequencing

    Time frame: Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months

  7. Correlative Analyses

    Blood biomarkers correlated with outcome to pembrolizumab or cetuximab, including Epstein-Barr virus plasma DNA titers

    Time frame: Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months

  8. Correlative Analyses

    Whole exome sequencing for neoantigen discovery

    Time frame: Newly obtained tumor specimen within 42 days of screening (when feasible)

07

Results

Posted Oct 1, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started33251010
Completed33251010
Not completed0000

Outcome measures

PrimaryOverall Response Rate

Proportion of patients with partial or complete response in tumor burden as defined by RECIST

Time frame:
6 months from the time of study enrollment
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsCohort 1Cohort 2Cohort 3Cohort 4
Overall Response Rate15706
SecondaryProgression Free Survival

No disease progression or death from any cause at 12 months from the time of study enrollment

Time frame:
12 months from the time of study enrollment
Reported as:
Median · month
Progression Free Survival
monthCohort 1Cohort 2Cohort 3Cohort 4
Progression Free Survival8.1 (3.8 to 11.2)7.1 (2.8 to 22.6)1.84 (0.34 to 99)5.5 (3 to 99)
SecondaryOverall Survival

Time from study enrollment to death from any cause

Time frame:
From the time of study enrollment until the date of death from any cause or completion of study, whichever came first, assessed up to 36 months
Reported as:
Median · months
Overall Survival
monthsCohort 1Cohort 2Cohort 3Cohort 4
Overall Survival16.5 (10.3 to 26.5)16 (7.3 to 34.3)4.73 (3.28 to 99)30.6 (23.1 to 99)
SecondaryDuration of Response

Time from documentation of tumor response to disease progression

Time frame:
Every 9 weeks from first on-treatment scan until disease progression or patient withdrawal from study or date of death from any cause, whichever came first, assessed up to 36 months

Results for this outcome have not been posted.

SecondaryNumber of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Pembrolizumab and Cetuximab, Graded According to NCI CTCAE v4.03

Description, grade (per CTCAE v4.03), seriousness and relatedness

Time frame:
Upon study enrollment, then subsequently at the first visit of each cycle (cycle length is 21 days), at the time of any adverse event, through end of treatment study visit, assessed up to 36 months

Results for this outcome have not been posted.

SecondaryCorrelative Analyses

Tumor tissue biomarkers correlated with outcome to pembrolizumab or cetuximab, such as PD-L1 expression, EGFR expression, p16 status, and immunophenotyping

Time frame:
Tumor specimens (archival or new specimen) should be obtained within 42 days of screening

Results for this outcome have not been posted.

SecondaryCorrelative Analyses

Blood biomarkers correlated with outcome to pembrolizumab or cetuximab, including T cell receptor (TCR) sequencing

Time frame:
Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months

Results for this outcome have not been posted.

SecondaryCorrelative Analyses

Blood biomarkers correlated with outcome to pembrolizumab or cetuximab, including Epstein-Barr virus plasma DNA titers

Time frame:
Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months

Results for this outcome have not been posted.

SecondaryCorrelative Analyses

Whole exome sequencing for neoantigen discovery

Time frame:
Newly obtained tumor specimen within 42 days of screening (when feasible)

Results for this outcome have not been posted.

Adverse events

Collected over 8 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 127/33 (81.8%)19/33 (57.6%)32/33 (97%)
Cohort 219/25 (76%)9/25 (36%)25/25 (100%)
Cohort 39/10 (90%)6/10 (60%)10/10 (100%)
Cohort 48/10 (80%)5/10 (50%)10/10 (100%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventCohort 1Cohort 2Cohort 3Cohort 4
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specifyNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/331/254/100/10
SepsisInfections and infestations5/331/250/103/10
Lung infectionInfections and infestations8/330/251/100/10
AspirationInjury, poisoning and procedural complications5/332/250/100/10
Febrile neutropeniaBlood and lymphatic system disorders0/330/250/101/10
Atrial fibrillationCardiac disorders0/330/251/100/10
Atrial flutterCardiac disorders0/330/251/100/10
Heart failureCardiac disorders0/332/251/101/10
Myocardial infarctionCardiac disorders0/330/250/101/10
Gastrointestinal fistulaGastrointestinal disorders0/330/251/100/10
Most frequent other events
Showing 10 of 112
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4
Rash acneiformSkin and subcutaneous tissue disorders25/3314/257/108/10
FatigueGeneral disorders12/3316/253/106/10
HypomagnesemiaMetabolism and nutrition disorders11/3311/256/103/10
Aspartate aminotransferase increasedInvestigations12/3310/253/102/10
Lymphocyte count decreasedInvestigations4/334/250/104/10
Dry skinSkin and subcutaneous tissue disorders13/337/253/104/10
Skin and subcutaneous tissue disorders - OtherSkin and subcutaneous tissue disorders8/338/251/104/10
AnemiaBlood and lymphatic system disorders7/339/253/101/10
NauseaGastrointestinal disorders11/337/253/102/10
Weight lossInvestigations11/335/251/101/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Cohort 4Total
Mean59.36 ± 10.9565.76 ± 11.9567.6 ± 9.5166.3 ± 15.6863.36 ± 12.08
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Female1131217
Male22229861
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
Hispanic or Latino43007
Not Hispanic or Latino272191067
Unknown or Not Reported21104
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
American Indian or Alaska Native00000
Asian40015
Native Hawaiian or Other Pacific Islander00000
Black or African American02103
White25198961
More than one race22004
Unknown or Not Reported22105
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Cohort 3Cohort 4Total
United States3325101078
08

Study locations

4 sites
  • UCSD Moores Cancer Center
    La Jolla, California 92093, United States
  • University of California Los Angeles Cancer Center
    Los Angeles, California 90095, United States
  • University of Michigan Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Washington School of Medicine Cancer Center
    St Louis, Missouri 63110, United States
09

References and documents

Publications

  • Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, Chai-Ho W, Oppelt P, Ghosh D, Bykowski J, Molinolo A, Pittman E, Estrada MV, Gold K, Daniels G, Lippman SM, Natsuhara A, Messer K, Cohen EEW. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):883-892. doi: 10.1016/S1470-2045(21)00136-4. Epub 2021 May 11. PubMed 33989559 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Jul 2025, 99 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 99 months is above that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2017
First posted
Mar 17, 2017
StartActual
Mar 28, 2017
Primary completionActual
Jul 21, 2025
CompletionActual
Sep 11, 2025
Results first posted
Oct 1, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 1, 2026
Secondary outcomes
6 edited
What changed in the outcomes
  • EditedProgression Free Survival ProbabilityTime frame: 12 months from the time of study enrollment
  • EditedNumber of patients with gradePatients With Grade 3 through gradeThrough Grade 5 adverse events that are relatedAdverse Events That Are Related to pembrolizumabPembrolizumab and cetuximabCetuximab, graded accordingGraded According to NCI CTCAE v4.03Time frame: Upon study enrollment, then subsequently at the first visit of each cycle (cycle length is 21 days), at the time of any adverse event, through end of treatment study visit, assessed up to 36 months
  • EditedCorrelative analysesAnalysesTime frame: Tumor specimens (archival or new specimen) should be obtained within 42 days of screening
  • EditedCorrelative analysesAnalysesTime frame: Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months
  • EditedCorrelative analysesAnalysesTime frame: Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months
  • EditedCorrelative analysesAnalysesTime frame: Newly obtained tumor specimen within 42 days of screening (when feasible)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Results posted
    Secondary outcomes 6 edited
    What changed in the outcomes
    • EditedProgression Free Survival ProbabilityTime frame: 12 months from the time of study enrollment
    • EditedNumber of patients with gradePatients With Grade 3 through gradeThrough Grade 5 adverse events that are relatedAdverse Events That Are Related to pembrolizumabPembrolizumab and cetuximabCetuximab, graded accordingGraded According to NCI CTCAE v4.03Time frame: Upon study enrollment, then subsequently at the first visit of each cycle (cycle length is 21 days), at the time of any adverse event, through end of treatment study visit, assessed up to 36 months
    • EditedCorrelative analysesAnalysesTime frame: Tumor specimens (archival or new specimen) should be obtained within 42 days of screening
    • EditedCorrelative analysesAnalysesTime frame: Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months
    • EditedCorrelative analysesAnalysesTime frame: Blood samples will be collected at screening, at time of first radiographic disease assessment on treatment (prior to initiation of cycle 4), and at time of clinical or radiographic disease progression, up to 36 months
    • EditedCorrelative analysesAnalysesTime frame: Newly obtained tumor specimen within 42 days of screening (when feasible)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03082534
Responsible party
Assuntina G. Sacco, MD (Assistant Professor, Medicine, University of California, San Diego) — Principal investigator
First posted
Mar 17, 2017
Start date
Mar 28, 2017
Primary completion
Jul 21, 2025
Completion
Sep 11, 2025
Results posted
Oct 1, 2026
Last update
Oct 1, 2026

Study contacts

Assuntina Sacco, M.D.
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Cetuximab

Start the discussion